Amneal Pharmaceuticals (AMRX) has a market capitalization of approximately $5.7B, trading at
Amneal Pharmaceuticals's trailing twelve-month P/E ratio is 47.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
Amneal Pharmaceuticals runs a net profit margin of 4.0%, a gross margin of 38.7%, and an operating margin of 11.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Amneal Pharmaceuticals reported revenue of
Amneal Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Amneal Pharmaceuticals carries a debt-to-equity ratio of -59.38x and a current ratio of 2.47x, with a market beta of 1.26. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Amneal Pharmaceuticals (AMRX) the key facts are: market cap $5.7B, P/E 47.1x, revenue
Get Amneal Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.